Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BioLineRx Ltd. (BLRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
07/17/2023 6-K Quarterly results
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "HaMa’ayan Street",
"REGISTRANT'S PRESS RELEASE DATED MAY 24, 2023;",
"HaMa’ayan Street",
"OPERATING AND FINANCIAL REVIEW"
04/25/2023 6-K Quarterly results
04/17/2023 6-K Quarterly results
03/22/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/22/2023 6-K Quarterly results
03/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas"
01/20/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"TEL AVIV, Israel, January 4, 2023 – – BioLineRx Ltd. , a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the Company’s clinical and medical functions. Her appointment is effective today, January 4, 2023."
12/20/2022 6-K Quarterly results
11/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"TEL AVIV, Israel, November 15, 2022",
"FINANCIAL STATEMENTS",
"OPERATING AND FINANCIAL REVIEW"
11/04/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
09/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Tel Aviv, Israel, September 27, 2022"
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"OPINION OF YIGAL ARNON & CO.",
"OPINION OF MCDERMOTT WILL & EMERY LLP",
"ARTICLE I. DEFINITIONS",
"FORM OF WARRANT TO BE ISSUED BY BIOLINERX LTD. ON SEPTEMBER 21, 2022",
"BIOLINERX LTD."
09/20/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/19/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "to this Report on Form 6-K",
"to this Report on Form 6-K"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "HaMa’ayan Street",
"SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO ITEM 601 OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE THEY BOTH ARE NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***].",
"HaMa’ayan Street"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BioLineRx Announces Submission of New Drug Application to FDA for Motixafortide in Stem Cell Mobilization"
09/09/2022 20-F/A Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
08/16/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/28/2022 6-K Quarterly results
06/16/2022 6-K Quarterly results
05/27/2022 6-K Quarterly results
05/11/2022 6-K Quarterly results
03/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"FOURTH QUARTER 2021 FINANCIAL RESULTS"
03/03/2022 6-K Quarterly results
02/11/2022 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 1% stake in BioLineRx Ltd.
01/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors"
01/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy